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  P
eer-reviewed medical journals 
are generally considered to be a 
source of unbiased and reliable 
information about drugs. But at the 
same time, most medical journals 
contain advertisements, almost all of 
which are for drugs, and which are, 
by their very nature, biased toward 
promoting sales of that drug. In this 
article, we address the purpose and 
effects of journal advertising, the 
possible reasons for pharmaceutical 
product domination of advertising 
pages, and the current policies and 
practices of representative journals. 
We also make recommendations for 
change.
    Advertising Drugs to Doctors: 
Scale and Impact
    Advertisements are intended to 
increase or maintain market share for 
targeted products. Pharmaceutical 
companies value print advertisements 
because they increase sales effectively 
[1]. In a survey of 125 pharmaceutical 
marketers, journal advertising tied 
with detailing (pharmaceutical sales 
representative visits to doctors) as 
the most effective promotional and 
educational vehicle for “announcing 
a new product/new indication” [2]. 
Robert Osborn, President of the 
Dowden Health Media Journal Group 
(Montvale, New Jersey, United States of 
America), has been quoted as stating, 
“Advertising in medical publications 
is highly regarded by pharmaceutical 
marketers because it has the ability to 
generate rapid awareness based on its 
cost-efﬁ  cient reach/frequency” [3].
    In 2003, drug companies spent 
US$448 million on advertising in 
medical journals [4]. Scott Neslin, a 
marketing professor who conducted 
the Return on Investment Analysis 
of Pharmaceutical Promotion study, 
found that the overall return on 
investment (calculated as the average 
increase in revenues per incremental 
dollar spent in any given month) on 
journal advertisements was US$5.00. 
The range was US$2.22–US$6.86, 
with larger and older brands at the 
higher end (an executive summary of 
the study is available at http:⁄⁄www.
rxpromoroi.org/rapp/index.
html). Another industry study of 
45 advertising campaigns found 
that journal advertising returned 
US$3.05 for advertising of unique 
products and US$2.46 for advertising 
of competitive established products 
(drugs that remain proﬁ  table despite 
competition—for example, sildenaﬁ  l 
[Viagra], which remains proﬁ  table 
despite now sharing the erectile 
dysfunction market with tadalaﬁ  l 
[Cialis] and vardenaﬁ  l [Levitra]) [5].
    Long-term returns may be even 
higher. While an advertisement 
in consumer magazines reaches 
potential purchasers individually, a 
pharmaceutical advertisement viewed 
by one physician could result in 
dozens or hundreds of drug purchases, 
especially if the drug is used over the 
long term. Although physicians believe 
that they prescribe based on impartial 
evidence, advertising has been shown 
to increase prescriptions for targeted 
drugs in a dose-related manner even 
when other promotional efforts are 
held constant [6].
    Although consumer goods 
are primarily sold by advertising, 
pharmaceutical advertisements 
directed at physicians are an adjunctive 
inﬂ  uence rather than a primary 
inﬂ  uence—in other words, journal 
advertisements are rarely a physician’s 
ﬁ  rst exposure to a product, but are 
reminders designed to reinforce other 
promotional efforts. Besides detailing, 
other efforts include direct mail, 
electronic communications (sometimes 
called “E-detailing”), and promotional 
events. These events include overtly 
commercial “dinner talks,” satellite 
presentations (company-sponsored 
expert talks piggybacked onto medical 
society meetings), and continuing 
medical education conferences, usually 
handled through medical education 
companies.
    Nevertheless, the pharmaceutical 
industry puts a high value on 
advertising its products in print 
journals. Milton Liebman, president of 
the Association of Medical Publishers 
(Westﬁ  eld, New Jersey, United States 
of America), writes, “Print promotion 
usually provides higher message 
penetration than detailing because 
print (most notably journals) obtains 
higher reach into the target audience 
with great consistency of message 
delivery” [7]. Marshal Paul, chairman 
of PERQ/HCI Research (Princeton, 
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New Jersey, United States of America), 
which conducts media research for the 
prescription drug industry, is quoted 
as stating, “Advertising magniﬁ  es the 
detailing effort at a fraction of detailing 
expense. In effect, detailing provides 
the power in the marketing effort and 
advertising provides the efﬁ  ciencies” 
[5]. 
    In an article called “A Medical 
Publisher Reminds Us: Don’t Forget 
the Gatekeepers,” which discusses 
how advertising drugs to doctors can 
increase drug sales, Thomas Pizor 
writes that “the physician can thwart, 
with a single comment or stroke of the 
pen, all of the investment of a DTC 
[direct to consumer] campaign.” He 
suggests: “Let professional messages 
complement consumer messages. The 
copy platform and graphics should 
work together for all those times the 
patient will not remember the brand 
name but might remember the art 
or headline” [8]. The author notes 
that prescribers “stand between the 
consumer and your drug,” and so “it 
seems intuitive that DTC promotion 
of Rx-only [prescription-only] drugs 
will work only when the prescriber 
is treated as a central ﬁ  gure in the 
marketing plan.” It is clear, then, that 
the pharmaceutical industry views drug 
advertisements in journals as “third 
party advertisements,” directed not at 
the end users of the targeted product 
(i.e., patients), but at the physician as 
gatekeeper between drug companies 
and patients. 
    Advertising Policies of Medical 
Journals: A Survey
    It is clear why drug companies advertise 
in medical journals, but why do they 
dominate display advertising pages? In 
other words, why do journals appear 
to publish advertisements for drugs 
much more frequently than for cars, 
computers, vacations, or other products 
of potential interest to doctors?
    We set out to explore this apparent 
monopoly by pharmaceutical 
companies of display (not classiﬁ  ed) 
advertising pages. We began by looking 
at whether medical journals do in 
fact state a preference for publishing 
advertisements for drugs and medical 
devices over other kinds of products. 
First, we examined the advertising 
policies of nine multispecialty medical 
journals: the   New England Journal of 
Medicine (NEJM)  , the   Journal of the 
American Medical Association (JAMA), 
Annals of Internal Medicine (Annals), 
PLoS Medicine, American Family 
Physician  , the   Lancet  , the   BMJ  , the 
  Canadian Medical Association Journal  , 
and the   Medical Journal of Australia  . 
Multispecialty journals were chosen 
because they receive the most 
advertising revenue. According to 
PERQ/HCI, in 2002, US$220,982,000 
was spent on advertising in 
multispecialty journals, almost ten 
times the amount spent on the 
runner-up, internal medicine journals 
(US$23,999,000) [9]. Advertising 
policies were obtained from the Web 
sites of journals or publishers, or by 
request. 
    Four of the ﬁ  ve North American 
journals with advertising policies 
posted on Web sites accepted only 
advertisements relevant to medicine; 
  PLoS Medicine   (an international 
journal published in the United 
States) accepts no advertisements 
for drugs or medical devices. Of the 
journals surveyed, only the   Canadian 
Medical Association Journal   speciﬁ  cally 
mentioned consumer goods, stating, 
“Products or services eligible for 
editorial display advertising should be 
germane to medical practice, medical 
education, professional development 
or health care delivery. Consumer 
products and nonﬁ  nancial services 
that are offered by responsible 
advertisers and that are of interest 
to physicians may be eligible.” The 
  Lancet  ,   BMJ  , and the   Medical Journal of 
Australia   did not address the relevance 
of product advertising in guidelines 
available on their Web sites (see 
sidebar).
      JAMA   states that “products or 
services eligible for advertising shall 
be germane to, effective in, and useful 
in (a) the practice of medicine, (b) 
medical education, and/or (c) health 
care delivery and shall be commercially 
available.” The   NEJM   states that “All 
advertising must be clearly germane 
to the practice of medicine.”   Annals   
states that “advertising will be accepted 
for products or services directly 
relevant to the practice of medicine” 
(examples include prescription and 
nonprescription drugs, medical 
equipment, books, journals, and 
medical services).   American Family 
Physician   requires that products or 
services “be germane to and effective 
in the practice of medicine” and notes 
that advertisements for non-health-
related commodities “will be accepted 
if they are determined to be in 
harmony with the stated purpose of the 
publication,” which is stated elsewhere 
as “to serve the medical profession and 
provide continuing medical education.”
    Although no policy restricted 
advertising only to pharmaceuticals, 
in practice, drug ads dominate. We 
surveyed display advertisements from 
all January and June issues of   JAMA   
from the last ten years in bound 
volumes at the Dahlgren Library, 
Georgetown University (Washington, 
D. C., United States of America). More 
than 95% of advertisements were for 
  Sources of Advertising Policies 
of Nine Multispecialty Medical 
Journals
   New England Journal of Medicine:
   http://nejmadsales.org/media/pdfs06/
06USRateCard.pdf; http://nejmadsales.
org/incentives/sponsorship.html
   Medical Journal of Australia:
   http://www.mja.com.au/classiﬁ  eds/
Advtg_index.html
   Canadian Medical Association Journal:
   http://www.cmaj.ca/misc/advertising.
shtml; http://www.cma.ca/index.cfm/
ci_id/25274/la_id/1.htm#restrictions
   PLoS Medicine:




   Annals of Internal Medicine:




   American Medical Association:
   http://pubs.ama-assn.org/misc/
adprinciples.pdf
   BMJ:
   http://www.bmjpg.com/advertising
   The  Lancet:
   http://www.elsmediakits.com/ratecards/
LANCET_display06.pdf
   American Family Physician:
   http://www.aafp.org/PreBuilt/afp_
ratecard_2006.pdf
    All Web sites accessed between 2005 
December 23 and 2006 January 3. 
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pharmaceutical products (see Table 1). 
The advertisements that were not for 
drugs were for health-related products, 
including medical books, medical Web 
sites, and computer products. Only 
military recruitment advertisements 
were unrelated to health care. 
    Flipping through any peer-
reviewed medical journal that accepts 
advertisements will show that the 
vast majority of advertisements are 
for prescription drugs; in the case of 
surgical journals, medical device ads 
are also prominent. A notable anomaly 
is the 1997 advertising menu of   JAMA  , 
which during that single year ran ads 
for Land Rover vehicles, Steinway 
pianos, and Wellcraft boats as well 
as for pork (“the other white meat”) 
and Quaker oatmeal. Intrigued by 
this apparent departure from usual 
advertising practice, we attempted 
to document what had inspired the 
expansion into consumer products and 
why it was abandoned; we interviewed 
  JAMA   editors and scanned public 
documents, but could not ﬁ  nd answers 
to our questions.
  Is It Only Drug Companies That Can 
Afford to Place Advertisements in 
Journals?
    Do display advertisements in medical 
journals feature mostly drugs because 
only pharmaceutical companies can 
afford such advertisements? Curious 
as to whether journal advertisements 
were beyond the means of consumer 
goods manufacturers, we compared 
advertising rates among journals 
afﬁ  liated with major medical societies 
against rates among several consumer 
magazines. We obtained rates and 
policies from publication Web sites or 
via E-mailed requests to advertising 
directors.
    Surprisingly, general medical journal 
advertisements are far less expensive 
than magazine advertisements (Table 
2; data sources for Table 2 are shown 
in Box 1). Adjusting for circulation 
does not eliminate disparities. For 
example, although   Vogue  ’s circulation 
of 1,150,000 is almost four times 
larger than   JAMA  ’s circulation of 
300,000, a   Vogue   advertisement costs 
almost seven times as much as a   JAMA   
advertisement.
     In 2004,   JAMA   and   NEJM  , the 
two largest and most inﬂ  uential 
US journals, had the highest 
revenues from advertising [10] and 
the cheapest advertising rates: a 
  JAMA   advertisement, only US$43 
per thousand readers; an   NEJM   
advertisement, only US$51 per 
thousand readers. In contrast, 
advertisements in consumer magazines 
range from US$86–US$110 per 
thousand readers (Table 2). 
    Some medical journals trumpet 
their bargain rates. Journals solicit 
pharmaceutical advertising by 
placing their own advertisements in 
  Medical Marketing and Media (MMM)  , 
a publication aimed primarily at 
pharmaceutical and other health-
care manufacturers. One   JAMA   
advertisement in   MMM   states, “A 
priceless audience. At a price you can 
afford” (as seen in the June 2002 issue 
of   MMM  ). An   Annals   advertisement 
states, “With an audience of more than 
90,000 internists (93% of whom are 
actively practicing physicians),   Annals   
has always been a smart buy” (as seen in 
the October 2000 issue of   MMM  ).
    Other advertisements placed by 
medical journals in   MMM   emphasize 
building relationships between doctors 
and drug company products. “Wisdom 
is for sharing,” is the headline of an 
advertisement from the   NEJM  , with a 
peculiar graphic of two people lying 
down, head to head, with what appears 
to be an egg between them. The 
advertisement goes on to say “Place 
your ad in the   New England Journal of 
Medicine   and make our relationship 
with the medical community yours” 
(as seen in the November 2003 issue 
of   MMM  ). Another advertisement, 
with a graphic of autumn leaves, is 
headlined “You’ll be   amazed   at what a 
  week   in   New England   can do,” and states, 
“Once a week, your advertising message 
is delivered to physicians who make 
decisions and inﬂ  uence the decisions of 
others.” And under the   NEJM   logo, the 
advertisement states, “The place to be 
for important news, important readers, 
important prescribers” (as seen in 
the October 2000 issue of   MMM  ). An 
advertisement for the   Archives   journals 
states “Connect in an environment 
of trust and reap the beneﬁ  ts of 
relationship marketing” (as seen in the 
January 2003 issue of   MMM  ).
    In contrast, a four-page 
advertisement for the Endocrine 
Society, which publishes the   Journal 
of Endocrinology and Metabolism  , 
is all business. “The highly cited 
articles published in JCE&M discuss 
the application of your company’s 
therapeutic products in the treatment 
of various endocrine disorders.” 
Other services are also touted: “we 
use our know-how to help you reach 
the industry’s thought leaders and 
maximize your return via our medical 
journals, annual meetings, continuing 
education and corporate development 
programs. In addition to this, patient 
education programs provided by The 
Hormone Foundation, our public 
education and outreach afﬁ  liate, 
provide more opportunities for 
increased public exposure” (as seen in 
the May 2002 issue of   MMM  ). 
    Advertising in   MMM   is no bargain. 
At US$423 per thousand exposed, the 
rate is higher than any other journal or 
magazine surveyed [11].
  Targeting  Speciﬁ  c Groups of 
Physicians
    Medical journals make prescribers 
available to pharmaceutical companies 
and offer a variety of ways of targeting 
  Table 1.   Advertisements in JAMA   
Year Number of 
Pharmaceutical Ads 
in All January and June 
Issues
Total Number of Ads in 
January and June Issues
Pharmaceutical Ads as a 
Percentage of Total Ads
1996 229 233 98%
1997 249 250 99%
1998 244 246 99%
1999 264 272 97%
2000 284 293 97%
2001 210 220 95%
2002 245 251 97%
2003 227 239 95%
2004 211 214 99%
  Information is from advertising indices of bound volumes, Dahlgren Library, Georgetown University.
  DOI:  10.1371/journal.pmed.0030130.t001 
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particular prescribers. Financial 
arrangements between journals 
and pharmaceutical companies 
result in different ads being sent to 
different physicians—so a New York 
cardiologist and an Omaha pediatrician 
who subscribe to the same journal 
may receive distinct medleys of 
advertisements. This is made possible 
by “insert” advertisements, which are 
prepared by advertisers and attached 
to the journal after production. 
Insert advertisements, which are 
more expensive than the “ﬁ  lm” 
advertisements printed with the journal 
content, enable advertisers to target 
“mini-demographics,” including those 
grouped by specialty, region, or most 
importantly, by prescribing proclivities. 
    Physicians who write the most 
prescriptions receive the most 
advertisements. The   NEJM   states 
“You can run your Cancer or HIV/
AIDS related product to a special 
list of high-prescribing physicians, 
including key oncology and infectious 
disease doctors” [12].   JAMA   also 
offers advertisers the chance to target 
“high-prescribing internal medicine 
physicians and other key specialists 
who prescribe AIDS-related [or 
‘cancer-related’] products” through a 
special, ad-dense version of   JAMA   that 
contains an average of “64 ad pages 
and 102 editorial pages” [13].   Annals   
states, “There are more internists in 
the United States (194,588 as of 2003) 
than family practitioners (97,051) 
and general practitioners (13,170) 
combined, and last year internists wrote 
nearly half a billion prescriptions. This 
group constitutes the ideal market for 
advertisers like you wishing to reach 
high-prescribing clinicians treating 
adult patients.”   Annals   also provides a 
list of the “top 20 diagnoses internists 
make” as well as the top 20 drug 
classes and top 20 brands prescribed 
by internists [14,15]. And   American 
Family Physician   offers “prescription 
data available for therapeutic classes 
and products, proﬁ  led by physician 
specialty, prescription writing and 
revenue levels. Data can be provided 
in desired format to active and 
prospective advertisers” [16].
    Research on journal advertisements 
is frustrating, because library journal 
issues usually contain only the ﬁ  lm 
advertisements, not the insert ads 
placed in subscriber issues. Bound 
volumes have even fewer ads. In order 
to save shelf space, many libraries, 
including the US National Library 
of Medicine, have advertisements 
removed from journals when they are 
sent for binding. 
  Advertising  as  “Education”
    As a crucial part of their business 
model, many medical journals rely 
on revenue from prescription drug 
advertisements. And the argument has 
been made that advertisements provide 
doctors with valuable information 
about drugs and diseases [17]. But are 
drug advertisements really educational? 
Pharmaceutical advertisements may 
provide descriptive and prescribing 
information, but their primary purpose 
is to increase the sales of new products 
or maintain sales of established 
products. There are more than 10,000 
drugs in the US market, but more than 
  Table 2.   Advertising Rates   






Circulation Cost of One-Time 
Full-Page Four-Color 
Advertisement
Cost per Thousand 
Readers Exposed
Medical journals  JAMA  (American Medical 
Association)
Weekly 344,652 US$14,847 US$43
 NEJM  (Massachusetts Medical 
Society)
Weekly 200,000 total (170,000 paid) US$10,120 US$51
 Annals  (American College of 
Physicians)
Twice a month 92,756 US$8,165 US$88
 American Family Physician  
(American Academy of Family 
Physicians)
Twice a month 186,780 US$12,260 US$66
 PLoS Medicine  (Public Library of 
Science)
Monthly Open access US$2,500 (no ads for dugs/
devices)
Not applicable (online, open 
access)
The   Lancet  Weekly 30,988 (global) US$6,430 US$207
 BMJ  (British Medical Association) Weekly  BMJ Clinical Research  
(hospital, 68,026)
 BMJ Clinical Research  
(US$7,128, £4,050)
 BMJ Clinical Research  
(US$105, £60) 
 BMJ General Practice  (27,514)  BMJ General Practice  
(US$7,128, £4,050)
 BMJ General Practice  (US$259, 
£147) 
 BMJ International  (13,482)  BMJ International  (US$5,438, 
£3,090)
 BMJ International  (US$403, 
£229)
 Medical Journal of Australia  
(Australian Medical Association)
Twice a month 28,500 US$3,501 (A$4,800)  US$123 (A$168)
Health-care marketing 
journal
 Medical Marketing and Media  Twice a month 14,750 US$6,243 US$423
Consumer magazines  Travel and Leisure  Monthly 950,000 US$91,905 US$97
 Architectural Digest  Monthly 800,000 US$86,635 US$108
 Business Week  Weekly 900,000 US$99,500 US$110
 Vogue Magazine  Monthly 1,219,614 US$104,490 US$86
 Forbes Magazine  Twice a month 900,000 US$96,150 US$106
 All  ﬁ  gures are from 2006 advertising rate cards or publication Web sites, accessed 20 March 2006. Sources are detailed in Box 1.
  DOI:  10.1371/journal.pmed.0030130.t002 
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half of promotional expenditures are 
spent on the 50 best-selling drugs [18]. 
New drugs are emphasized.
    New drugs are not always superior 
to old drugs, and best sellers are not 
always better than their competitors. 
If medical journals accepted only 
advertisements for drugs proven 
superior in comparative trials, the 
argument that drug advertisements 
are educational could be rationalized. 
No journal, however, requires 
demonstration of product superiority as 
a condition for advertising. Competing 
drugs regularly cohabit in the same 
journal (and when they do cohabit, 
they may be kept apart—the advertising 
rate card of the   Annals of Internal 
Medicine   states that “Competitive 
products are separated by no fewer 
than four pages for primary indication 
only, as reﬂ  ected in the ad content.”
    The “advertising-as-education” 
argument actually reached the US 
Supreme Court. In 1975, the American 
College of Physicians, publisher 
of   Annals  , argued that proﬁ  ts on 
pharmaceutical advertising should not 
be taxed because the advertisements 
were educational and thus related to the 
journal’s tax-exempt status [19]. The 
US Claims court disagreed, noting that 
any educational function was incidental 
to revenue-raising function, and that 
“The evidence is clear that plaintiff did 
not use the advertising to provide its 
readers a comprehensive or systematic 
presentation of any aspect of the goods 
or services publicized. Those companies 
willing to pay for advertising space 
got it; others did not. Moreover, some 
of the advertising was for established 
drugs or devices and was repeated from 
one month to another, undermining 
the suggestion that the advertising was 
principally designed to alert readers of 
recent developments” [20].
    Reversed by the Court of Appeals 
[21], the case went to the US Supreme 
Court, which reversed the decision of 
the appeals court [22]. Writing for the 
majority, Justice Thurgood Marshall 
wrote, “we are bound to conclude that 
the advertising in Annals does not 
contribute importantly to the Journal’s 
educational purposes” [20].
    Drug advertisements are not public 
service announcements. A review 
of 109 full-page pharmaceutical 
advertisements concluded that 44% 
would lead to improper prescribing 
if a physician relied only on the 
information presented in the 
advertisement [23]. A study by Cooper 
and Schriger of ten US journals found 
that 126 of 438 advertisements with 
medical claims contained no medical 
references. Of 312 advertisements 
with references, 55% cited journal 
articles and 19% cited “data on 
ﬁ  le” (proprietary information that 
companies are not obligated to provide 
to clinicians). Only 20% of references 
to data on ﬁ  le were available [24]. 
Two other studies found similar 
results: data availability for references 
in advertisements was 20% [25] and 
26% [26]. Published studies cited by 
advertisements are more likely to be 
company-sponsored; in Cooper and 
Schriger’s survey, 58% of original 
research cited was sponsored by or had 
an author afﬁ  liated with the product 
manufacturer, compared with 8% of 
references to original research within 
research articles [24].
    Can Medical Journals Wean 
Themselves off Drug Advertising?
    Publishing is expensive, and medical 
journals obviously need a business 
model to be sustainable [27]. 
Advertisements are only a part of 
the ﬁ  nancial relationship between 
pharmaceutical companies and most 
medical journals. Pharmaceutical 
companies are the primary purchaser 
of reprints, and may buy thousands 
of reprints if they are advantageous 
to the drugs that they manufacture. 
Additionally, drug companies “sponsor” 
subscriptions [28] provided without 
cost to targeted populations (referred 
to as “controlled” subscriptions). 
The recently deceased   BMJ USA   (a 
derivative publication of the weekly 
  BMJ  , containing selected articles, more 
advertisements than the weekly   BMJ  , 
and some US-speciﬁ  c content) was 
almost 100% controlled, with all but 
25 of 95,000 subscriptions apparently 
sponsored by pharmaceutical 
companies. Most subscriptions were 
sent to high prescribers [29].
    The   Lancet   tells potential purchasers 
of sponsored subscriptions that 
“three quarters of all respondents 
[recipients of sponsored subscriptions 
who responded to a Lancet-
commissioned survey] were aware 
   Journal of the American Medical 
Association: 
   http://pubs.ama-assn.org/misc/
jamarates.pdf 
   The New England Journal 
of Medicine: 








   Medical Journal of Australia: 
   http://www.mja.com.au/classiﬁ  eds/
Advtg_index.html
   BMJ: 
   http://www.bmjpg.com/advertising
   Canadian Medical Association 
Journal: 
   http://www.cmaj.ca/pdfs/cmaj.pdf
   The  Lancet: 
   http://www.elsmediakits.com/ratecards/
LANCET_display06.pdf 
   American Family Physician: 
   http://www.aafp.org/PreBuilt/
afp_ratecard_2006.pdf 
   Annals of Internal Medicine: 
   http://www.acponline.org/journals/
advert/annals_rates06.pdf 
   PLoS: 
   http://www.plos.org/support/index.html 
   Medical Marketing and Media:
   http://www.mmm-online.com/content/
ﬁ  leadmin/ﬁ  les/mediainfo/onesheet.pdf
   Forbes:
   http://www.forbesmedia.com/forbes/
forbrates.php 
   Vogue:
   http://www.srds.com/listinglink/
advertisinginfo/vogue 
   Architectural Digest:
   http://www.condenastmediakit.com/ad/
genrates.cfm 
   Travel and Leisure:
   http://www.tlmediakit.com/nat_rates06.
cfm 
   Business Week:
   http://mediakit.businessweek.com/PDF 
  Box 1. Sources of Data for Table 2
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that their subscription to   The Lancet   
was sponsored by a pharmaceutical 
company. Moreover, one half also 
recalled, on an   unaided   [bold text in 
the original quotation] basis, the name 
of the sponsoring company” [30]. 
“Arm your sales force with sponsored 
subscriptions to offer physicians on sales 
calls,” the   NEJM   suggests, promoting its 
“coverwrap, consisting of a customized 
cover and prime advertising pages, 
[which] delivers your product with 
your distinct message to thousands of 
physicians a week” (http:⁄⁄nejmadsales.
org/media/pdfs05/NEJMcoverwrap05.
pdf). The   NEJM   also offers to “conduct 
complimentary research for you 
among sponsored subscribers to 
validate the success of your program” 
(http:⁄⁄nejmadsales.org/incentives/
sponsorship.html).
    Journal advertisements generate 
proﬁ  ts not only for pharmaceutical 
companies and medical journals, but 
also for the physician organizations 
that publish the journals. In 1996, 
ﬁ  ve of six physician organizations 
raised 10% or more of their total 
annual revenue from pharmaceutical 
company advertising in afﬁ  liated 
medical journals; the proportion of 
total revenues ranged from 2.1% to 
31.3% [31]. In 2004, advertising in 
American Medical Association (AMA) 
publications constituted 15.1% of total 
AMA revenues [32]. The AMA received 
US$40.7 million from advertising in 
publications (presumably including 
  JAMA  , the   Archives   journals, and 
  American Medical News  ), more than 
twice the US$17.5 million received 
from subscriptions [32]. 
    By accepting only advertisements for 
drugs and medical devices, medical 
journals have accepted an exclusive 
and dependent relationship with 
corporations. Perhaps the distance 
between the prescribing physician 
and the purchase of the advertised 
product contributes to the perception 
that drug advertisements in journals 
are somehow more professional than 
advertisements for goods hawked 
directly to the consumer. However, all 
advertising campaigns are designed to 
create positive feelings about a brand, 
to saturate a targeted population’s 
environment with a brand name, and 
to sell the product. 
    In consumer magazines, article 
content often caters to, or is ordered 
by, advertisers, and publishing articles 
that displease advertisers can ﬁ  nancially 
jeopardize the publication. Medical 
journals are similarly prone to leash-
yanking by advertisers.
    A 1995 survey of North American 
journal editors found that 12% noted 
conﬂ  icts between advertisers’ wishes 
and editorial decisions, and 21% 
reported that they had no control 
over advertisements [33]. In 1992, a 
study in   Annals   criticized the accuracy 
of advertisements in journals [23]. 
Several large pharmaceutical companies 
subsequently withdrew advertising in that 
journal [25], costing an estimated US$1 
million to US$1.5 million in lost revenue 
[34]. Ensuing tension with the American 
College of Physicians contributed to 
the 1993 resignations of the coeditors, 
Robert and Suzanne Fletcher. In an 
interview, Robert Fletcher said, “The 
pharmaceutical industry showed us 
that the advertising dollar could be a 
two-edged sword, a carrot or a stick. 
If you ever wondered whether they 
play hardball, that was a pretty good 
demonstration that they do” [35].
    At times, advertising departments 
appear to inﬂ  uence editorial decisions. 
In 2001, the advertising department 
of   Annals   expressed concern about a 
planned editorial on high drug costs. 
These concerns were allayed when 
the editor invited a commentary 
from the Pharmaceutical Research 
and Manufacturers Association 
(Washington, D. C., United States of 
America), which commissioned a piece 
from a conservative thinktank, the 
American Enterprise Institute for Public 
Policy Research (Washington, D. C., 
United States of America) [35]. In 2004, 
an editor at   Dialysis and Transplantation   
explained to an author that although 
the author’s article had passed both 
editorial and peer review, the marketing 
department had rejected it [36]. The 
journal later reversed its decision, 
but the author refused to resubmit it, 
stating that “This episode has convinced 
us that the responsible action on our 
part is to continue our current efforts 
to have this manuscript published in a 
more academic journal” [37].
    Several authors have suggested 
that dependence on drug advertising 
endangers the independence of medical 
journals [38] and have advocated other 
sources of revenue [20]. Although 
physicians would be expected to be a 
desirable audience for purveyors of cars, 
golf clubs, cruises, and luxury goods, 
advertisements for consumer goods 
in medical journals are conspicuous 
by their absence. Orentlicher and 
Hehir have argued compellingly that if 
advertisements for luxury goods were 
accepted, “journals would have a larger 
pool of companies to which they could 
sell advertising space, and they would 
reduce the conﬂ  ict of interest that arises 
from the practice of only accepting 
health care advertisements. This 
suggests that health care companies 
are not the ﬁ  rst place medical journals 
should look for advertising. Rather, 
they are the last place medical journals 
should look” [19].
    Dependence on a single industry 
can be ﬁ  nancially disastrous for a 
journal that displeases its corporate 
funders. Dependence on prescription 
drug advertising is also ﬁ  nancially 
risky, as the journal risks closure if 
it can’t attract sufﬁ  cient revenue—
indeed,   BMJ USA   has folded because 
“it has fallen victim to the widespread 
downturn in US pharmaceutical 
advertising and has become ﬁ  nancially 
unsustainable for the BMJ Publishing 
Group” [39]. Accepting advertising for 
consumer goods removes the conﬂ  ict 
of interest inherent in pharmaceutical 
advertising, but more importantly may 
free editors from the threat of lost 
revenue. It is disturbing that medical 
journals appear to have exclusive, 
largely undeclared arrangements with 
pharmaceutical companies. It could 
even be argued that it is poor business 
practice to forego more lucrative 
advertisements in order to provide 
cut-rate advertising to manufacturers 
of drugs and devices. If purveyors 
of consumer goods are willing 
to advertise in medical journals, 
replacing drug advertisements with 
advertisements for consumer goods 
could bolster both the bottom line and 
editorial freedom.
    Another option is to eschew journal 
advertising altogether. Some journals 
refuse to advertise drugs or devices, 
depending instead on other sources 
of income. The non-proﬁ  t journal 
  PLoS Medicine  , for example, uses a 
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  At times, advertising 
departments appear 
to inﬂ  uence editorial 
decisions. PLoS Medicine  |  www.plosmedicine.org 0768
business model that includes support 
from foundations, from institutional 
memberships, and from asking research 
funders to pay a publication charge for 
accepted research papers (http:⁄⁄www.
plos.org/support/index.html). 
  Conclusion
    Clinicians rely on medical journals 
for scholarly articles and the latest 
information on drugs and devices. 
Advertisements in these journals are 
unreliable sources of information, since 
they “educate” physicians to prescribe 
the newest, most expensive drugs 
(which may not be any superior to 
existing, less expensive alternatives).
    The scholarly nature of journals 
confers credibility on both articles and 
advertisements within their pages. By 
exclusively featuring advertisements 
for drugs and devices, medical journals 
implicitly endorse corporate promotion 
of the most proﬁ  table products. 
Advertisements and other ﬁ  nancial 
arrangements with pharmaceutical 
companies compromise the objectivity 
of journals.
    The primary obligation of 
industry is to make money for its 
stockholders. The primary obligation 
of journals should be to physicians 
and their patients, who depend on 
the accuracy of information within 
these publications. Medical journals 
should not accept advertisements from 
pharmaceutical companies, medical 
device companies, or other industries 
“relevant to medicine.”   
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